BioStem Technologies, Inc. (BSEM) Misses Q3 EPS by 44c; offers guidance

BioStem Technologies, Inc. (NASDAQ: BSEM) reported Q3 EPS of ($0.52), $0.44 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11 million.

GUIDANCE:

BioStem Technologies, Inc. sees FY2026 revenue of $26-29 million, versus the consensus of $29.004 million.

For earnings history and earnings-related data on BioStem Technologies, Inc. (BSEM) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
• Deutsche Bank Upgrades Huizhou Desay Sv Automotive Co (002920:CH) to Hold